LAWRENCE, Mass., Sept. 1, 2015 /PRNewswire/
-- NxStage® Medical, Inc. (Nasdaq: NXTM) a
leading manufacturer of dialysis products, today announced online
publication in the American Journal of Kidney Disease (AJKD)
of results from the largest study of its kind that assessed
relative mortality on frequent home hemodialysis (HHD) versus
peritoneal dialysis (PD) as well as relative all-cause
hospitalization. The data show that frequent HHD patients have a
lower risk of death, hospitalization and therapy attrition
than PD patients.
The study, Mortality, Hospitalization, and Technique
Failure in Daily Home Hemodialysis and Matched Peritoneal Dialysis
Patients: A Matched Cohort Study, was conducted by
Eric Weinhandl, PhD, MS, affiliated
with the Chronic Disease Research Group (CDRG). The
intention-to-treat analysis showed that frequent HHD patients have
a 20 percent lower risk of death, 8 percent lower risk of
hospitalization and 37 percent lower risk of therapy attrition than
PD patients.
A 38-factor algorithm matched 4,201 frequent HHD patients with
4,201 PD patients. Results showed lower risks of death due to
cardiovascular disease, infection, and either cachexia or dialysis
withdrawal with frequent HHD therapy. Results also showed 15
percent lower risk of hospitalization due to cardiovascular disease
and 11 percent lower risk of hospitalization due to infection with
frequent HHD therapy.
"Home dialysis is growing, but there are few studies that
compare clinical outcomes with HHD and PD," said Weinhandl. "This
study suggests that frequent HHD may offer important advantages,
especially with respect to reducing cardiovascular risk and keeping
patients in their homes."
The study also included detailed analysis of patients that began
dialyzing in their homes within the first six months of being
diagnosed with end stage renal disease, during which time patients
typically start PD. In this group, frequent HHD patients had
similar risks of death and hospitalization as PD patients and 30
percent lower risk of therapy attrition.
"Published studies consistently report improved survival,
improved quality of life and other important benefits for home
hemodialysis patients," said NxStage president, Joseph Turk. "These particular findings
challenge conventional thinking within the renal community and
should compel clinicians to consider frequent HHD a life-changing
therapy choice for patients who are considering at home
dialysis."
To view the published study, please visit
http://www.ajkd.org/article/S0272-6386(15)01018-5/abstract.
For more information about the NxStage System One™
and home hemodialysis, please visit www.nxstage.com.
Despite the health benefits that home hemodialysis may
provide to those with chronic kidney disease, this form of therapy
is not for everyone. The reported benefits of home and more
frequent hemodialysis may not be experienced by all patients. The
risks associated with hemodialysis treatments in any environment
include, but are not limited to, high blood pressure, fluid
overload, low blood pressure, heart-related issues, and vascular
access complications. The medical devices used in hemodialysis
therapies may add additional risks including air entering the
bloodstream and blood loss due to clotting or accidental
disconnection of the blood tubing set. Certain risks are unique to
the home. Treatments at home are done without the presence of
medical personnel and on-site technical support. Patients and their
partners must be trained on what to do and how to get medical or
technical help if needed.
About the NxStage System One
The NxStage System One is
the first and only truly portable hemodialysis system cleared
specifically by the FDA for home hemodialysis and home
nocturnal hemodialysis. Its simplicity and revolutionary size (just
over a foot tall) are intended to allow convenient use in patients'
homes and give patients the freedom to travel with their therapy.
When combined with the NxStage PureFlow SL Dialysis Preparation
System, patients are able to further simplify, using ordinary tap
water to create dialysis fluid on demand. Unlike conventional
hemodialysis systems, the System One requires no special
infrastructure to operate. Under the guidance of their physician,
patients can use the NxStage System One, with their trained
partners, where, how and when it best meets their needs, including
while they are sleeping - at home or on vacation and at a medically
appropriate treatment frequency. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical
Inc. (Nasdaq: NXTM) is a medical device company,
headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets
innovative products for the treatment of ESRD and acute kidney
failure. For more information on NxStage and its products, please
visit the Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and Exchange
Commission, including the Quarterly Report on Form 10-Q for the
quarter ended June 30, 2015. NxStage is under no obligation to
(and expressly disclaims any such obligation to) update or alter
its forward-looking statements, whether as a result of new
information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
Logo - http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
Logo - http://photos.prnewswire.com/prnh/20150624/225341
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/american-journal-of-kidney-disease-publication-confirms-significant-patient-advantages-with-hhd-versus-pd-300135630.html
SOURCE NxStage Medical, Inc.